AstraZeneca

6 Juni 2022 08:20

Enhertu reduced the risk of disease progression or death by 50% vs. chemotherapy in patients with HER2-low metastatic breast cancer with HR-positive and HR-negative disease

Enhertu reduced the risk of disease progression or death by 50% vs. chemotherapy in patients with HER2-low metastatic breast cancer with HR-positive and HR-negative disease. AstraZeneca and Daiichi Sankyo’s Enhertu also improved median overall survival by more than 6 months vs. chemotherapy in all patients evaluated in DESTINY-Breast04.

2 Juni 2022 08:00

AstraZeneca’s Pascal Soriot awarded British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic

AstraZeneca’s Chief Executive Officer, Pascal Soriot, today received a British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic in the Queen’s Birthday Honours 2022.

23 Maj 2022 08:20

Vaxzevria approved in the EU as third dose booster against COVID-19

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the European Medicine Agency (EMA) as a third dose booster in adults.

23 Maj 2022 08:16

AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022

AstraZeneca advances its ambition to redefine cancer care with new data to be presented across its diverse and industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, 3 to 7 June 2022.

16 Maj 2022 09:00

PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation

First time an albuterol/budesonide fixed-dose combination rescue medication has been shown to reduce severe exacerbations. MANDALA Phase III trial results published in the New England Journal of Medicine and presented at ATS 2022 International Conference.

5 Maj 2022 08:11

Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.

$Farxiga met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction$

5 Maj 2022 08:05

Farxiga met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction

High-level results from the DELIVER Phase III trial showed AstraZeneca’s Farxiga (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart failure (HF).

5 Maj 2022 08:00

Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder

Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that Ultomiris achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) compared to the external placebo arm from the pivotal Soliris PREVENT clinical trial.

4 Maj 2022 08:01

Imfinzi plus chemotherapy granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer based on TOPAZ-1 Phase III trial

AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer (BTC).

29 April 2022 08:08

AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

AstraZeneca today announced plans to open a new site at the heart of the Cambridge, MA, life sciences and innovation hub.

29 April 2022 08:02

AstraZeneca PLC:s resultatrapport för första kvartalet 2022

En stark inledning på året. Fortsatta investeringar i forskningsportföljen för att driva hållbar och långsiktig tillväxt.

28 April 2022 08:10

Ultomiris approved in the US for adults with generalised myasthenia gravis

Ultomiris (ravulizumab-cwvz) has been approved in the US for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, which represents 80% of people living with the disease.

Nyhetsarkiv